Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 7 de 7
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Environ Microbiol ; 26(6): e16660, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38822592

RÉSUMÉ

Over 6 years, we conducted an extensive survey of spontaneous grape fermentations, examining 3105 fungal microbiomes across 14 distinct grape-growing regions. Our investigation into the biodiversity of these fermentations revealed that a small number of highly abundant genera form the core of the initial grape juice microbiome. Consistent with previous studies, we found that the region of origin had the most significant impact on microbial diversity patterns. We also discovered that certain taxa were consistently associated with specific geographical locations and grape varieties, although these taxa represented only a minor portion of the overall diversity in our dataset. Through unsupervised clustering and dimensionality reduction analysis, we identified three unique community types, each exhibiting variations in the abundance of key genera. When we projected these genera onto global branches, it suggested that microbiomes transition between these three broad community types. We further investigated the microbial community composition throughout the fermentation process. Our observations indicated that the initial microbial community composition could predict the diversity during the early stages of fermentation. Notably, Hanseniaspora uvarum emerged as the primary non-Saccharomyces species within this large collection of samples.


Sujet(s)
Biodiversité , Fermentation , Champignons , Mycobiome , Vitis , Vitis/microbiologie , Champignons/classification , Champignons/génétique , Champignons/métabolisme , Champignons/isolement et purification , Microbiote
2.
PLoS Genet ; 20(3): e1011223, 2024 Mar.
Article de Anglais | MEDLINE | ID: mdl-38517929

RÉSUMÉ

Cultural exchange of fermentation techniques has driven the spread of Saccharomyces cerevisiae across the globe, establishing natural populations in many countries. Despite this, Oceania is thought to lack native populations of S. cerevisiae, only being introduced after colonisation. Here we investigate the genomic landscape of 411 S. cerevisiae isolated from spontaneous grape fermentations in Australia across multiple locations, years, and grape cultivars. Spontaneous fermentations contained highly recombined mosaic strains that exhibited high levels of genome instability. Assigning genomic windows to putative ancestral origin revealed that few closely related starter lineages have come to dominate the genetic landscape, contributing most of the genetic variation. Fine-scale phylogenetic analysis of loci not observed in strains of commercial wine origin identified widespread admixture with European derived beer yeast along with three independent admixture events from potentially endemic Oceanic lineages that was associated with genome instability. Finally, we investigated Australian ecological niches for basal isolates, identifying phylogenetically distinct S. cerevisiae of non-European, non-domesticated origin associated with admixture loci. Our results illustrate the effect commercial use of microbes may have on local microorganism genetic diversity and demonstrates the presence of non-domesticated, potentially endemic lineages of S. cerevisiae in Australian niches that are actively admixing.


Sujet(s)
Vitis , Vin , Saccharomyces cerevisiae/génétique , Vitis/génétique , Phylogenèse , Australie , Vin/analyse , Génomique , Instabilité du génome/génétique , Recombinaison génétique , Fermentation
3.
Stem Cells ; 38(10): 1292-1306, 2020 10 01.
Article de Anglais | MEDLINE | ID: mdl-32621788

RÉSUMÉ

Inhibition of E-cad in mouse embryonic stem cells (mESCs) leads to a switch from LIF-BMP to Activin/Nodal-dependent pluripotency, consistent with transition from a naïve to primed pluripotent phenotype. We have used both genetic ablation and steric inhibition of E-cad function in mESCs to assess alterations to phenotype using quantitative mass spectrometry analysis, network models, and functional assays. Proteomic analyses revealed that one third of detected proteins were altered in E-cad null mESCs (Ecad-/- mESCs) compared to wild type (624 proteins were downregulated and 705 were proteins upregulated). Network pathway analysis and subsequent cellular flux assays confirmed a metabolic shift from oxidative phosphorylation (OXPHOS) to aerobic glycolysis, specifically through mitochondrial complex III downregulation and hypoxia inducible factor 1a target upregulation. Central to this was the transcriptional coactivator EP300. E-cad is a well-known tumor suppressor, its downregulation during cancer initiation and metastasis can be linked to the metabolic switch known as Warburg effect. This study highlights a phenomena found in both primed pluripotent state and cancer stemness and links it to loss of E-cad. Data are available via ProteomeXchange with identifier PXD012679.


Sujet(s)
Cadhérines/métabolisme , Cellules souches embryonnaires de souris/métabolisme , Cellules souches pluripotentes/métabolisme , Animaux , Cycle cellulaire/génétique , Cellules cultivées , Protéine p300-E1A/métabolisme , Complexe III de la chaîne respiratoire/métabolisme , Métabolisme énergétique , Acides gras/métabolisme , Régulation de l'expression des gènes , Glycolyse , Souris , Souris knockout , Cellules souches tumorales/métabolisme , Protéome/métabolisme , Protéomique , Espèces réactives de l'oxygène/métabolisme
4.
Med J Aust ; 210(5): 227-235, 2019 03.
Article de Anglais | MEDLINE | ID: mdl-30739331

RÉSUMÉ

INTRODUCTION: Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disease and, globally, more than an estimated 10 million people have it yearly. It is a chronic and recurrent disease. The symptoms of VTE are non-specific and the diagnosis should actively be sought once considered. The mainstay of VTE treatment is anticoagulation, with few patients requiring additional intervention. A working group of experts in the area recently completed an evidence-based guideline for the diagnosis and management of DVT and PE on behalf of the Thrombosis and Haemostasis Society of Australia and New Zealand (www.thanz.org.au/resources/thanz-guidelines). MAIN RECOMMENDATIONS: The diagnosis of VTE should be established with imaging; it may be excluded by the use of clinical prediction rules combined with D-dimer testing. Proximal DVT or PE caused by a major surgery or trauma that is no longer present should be treated with anticoagulant therapy for 3 months. Proximal DVT or PE that is unprovoked or associated with a transient risk factor (non-surgical) should be treated with anticoagulant therapy for 3-6 months. Proximal DVT or PE that is recurrent (two or more) and provoked by active cancer or antiphospholipid syndrome should receive extended anticoagulation. Distal DVT caused by a major provoking factor that is no longer present should be treated with anticoagulant therapy for 6 weeks. For patients continuing with extended anticoagulant therapy, either therapeutic or low dose direct oral anticoagulants can be prescribed and is preferred over warfarin in the absence of contraindications. Routine thrombophilia testing is not indicated. Thrombolysis or a suitable alternative is indicated for massive (haemodynamically unstable) PE. CHANGES IN MANAGEMENT AS A RESULT OF THE GUIDELINE: Most patients with acute VTE should be treated with a factor Xa inhibitor and be assessed for extended anticoagulation.


Sujet(s)
Embolie pulmonaire , Thromboembolisme veineux , Anticoagulants/usage thérapeutique , Australie , Angiographie par tomodensitométrie , Médecine factuelle , Humains , Nouvelle-Zélande , Embolie pulmonaire/diagnostic , Embolie pulmonaire/thérapie , Récidive , Facteurs de risque , Thromboembolisme veineux/diagnostic , Thromboembolisme veineux/thérapie , Warfarine/usage thérapeutique
5.
Mol Microbiol ; 64(4): 1000-13, 2007 May.
Article de Anglais | MEDLINE | ID: mdl-17501923

RÉSUMÉ

The histone-like nucleoid structuring protein (H-NS) is a global transcriptional regulator that influences stress response and virulence pathways in Gram-negative bacteria. H-NS also promotes Tn10 transposition by binding directly to the transpososome and inducing a conformational change in the transpososome that favours intermolecular transposition events. H-NS binds preferentially to curved DNA and can bend non-curved DNA, it self-oligomerizes and can interact with other proteins. To determine what functions of H-NS are important in promoting Tn10 transposition, we have examined the ability of two mutant forms of H-NS, P116S and 1-64, to act in Tn10 transposition. We provide evidence that the initial interaction of H-NS with the transpososome is dependent on H-NS binding to a specific structure in DNA flanking the transposon end. Additional molecules of H-NS then bind within the transposon end. This latter event appears to be directed by H-NS binding to the Tn10 transposase protein, and is important in maintaining the transpososome in a conformation that promotes intermolecular transposition. The binding of H-NS to a transposase protein is a novel function for this important regulatory molecule.


Sujet(s)
Protéines bactériennes/métabolisme , Éléments transposables d'ADN/physiologie , ADN bactérien/métabolisme , Protéines de liaison à l'ADN/métabolisme , Transposases/métabolisme , Protéines bactériennes/génétique , Technique de Western , Prise d'empreintes sur l'ADN , Protéines de liaison à l'ADN/génétique , Test de retard de migration électrophorétique , Mutation faux-sens , Liaison aux protéines , Délétion de séquence
6.
J Clin Invest ; 116(8): 2290-6, 2006 Aug.
Article de Anglais | MEDLINE | ID: mdl-16878173

RÉSUMÉ

Neurotoxicity from accumulation of misfolded/mutant proteins is thought to drive pathogenesis in neurodegenerative diseases. Since decreasing levels of proteins responsible for such accumulations is likely to ameliorate disease, a therapeutic strategy has been developed to downregulate almost any gene in the CNS. Modified antisense oligonucleotides, continuously infused intraventricularly, have been demonstrated to distribute widely throughout the CNS of rodents and primates, including the regions affected in the major neurodegenerative diseases. Using this route of administration, we found that antisense oligonucleotides to superoxide dismutase 1 (SOD1), one of the most abundant brain proteins, reduced both SOD1 protein and mRNA levels throughout the brain and spinal cord. Treatment initiated near onset significantly slowed disease progression in a model of amyotrophic lateral sclerosis (ALS) caused by a mutation in SOD1. This suggests that direct delivery of antisense oligonucleotides could be an effective, dosage-regulatable means of treating neurodegenerative diseases, including ALS, where appropriate target proteins are known.


Sujet(s)
Maladies neurodégénératives/traitement médicamenteux , Oligonucléotides antisens/usage thérapeutique , Animaux , Séquence nucléotidique , Fibroblastes/effets des médicaments et des substances chimiques , Fibroblastes/enzymologie , Macaca mulatta , Maladies du motoneurone/enzymologie , Oligonucléotides antisens/métabolisme , Oligonucléotides antisens/pharmacologie , Pliage des protéines , ARN messager/génétique , Rats , Superoxide dismutase/génétique , Superoxide dismutase-1 , Fonction ventriculaire
7.
J Cell Biol ; 158(4): 681-93, 2002 Aug 19.
Article de Anglais | MEDLINE | ID: mdl-12186852

RÉSUMÉ

The COOH-terminal tail of mammalian neurofilament heavy subunit (NF-H), the largest neurofilament subunit, contains 44-51 lysine-serine-proline repeats that are nearly stoichiometrically phosphorylated after assembly into neurofilaments in axons. Phosphorylation of these repeats has been implicated in promotion of radial growth of axons, control of nearest neighbor distances between neurofilaments or from neurofilaments to other structural components in axons, and as a determinant of slow axonal transport. These roles have now been tested through analysis of mice in which the NF-H gene was replaced by one deleted in the NF-H tail. Loss of the NF-H tail and all of its phosphorylation sites does not affect the number of neurofilaments, alter the ratios of the three neurofilament subunits, or affect the number of microtubules in axons. Additionally, it does not reduce interfilament spacing of most neurofilaments, the speed of action potential propagation, or mature cross-sectional areas of large motor or sensory axons, although its absence slows the speed of acquisition of normal diameters. Most surprisingly, at least in optic nerve axons, loss of the NF-H tail does not affect the rate of transport of neurofilament subunits.


Sujet(s)
Transport axonal/physiologie , Axones/ultrastructure , Microtubules/métabolisme , Protéines neurofilamenteuses/métabolisme , Tubuline/métabolisme , Potentiels d'action/physiologie , Substitution d'acide aminé , Animaux , Axones/physiologie , Division cellulaire/physiologie , Cellules cultivées , Délétion de gène , Souris , Gaine de myéline , Protéines neurofilamenteuses/génétique , Neurones afférents/cytologie , Neurones afférents/physiologie , Phosphorylation , Sous-unités de protéines , Séquences répétées d'acides aminés
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE